• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Kos the Specialty Pharmaceutical Company is Currently Developing New Products.

Posted on: Friday, 3 February 2006, 12:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c32127) has announced the addition of the Espicom Business Intelligence Ltd report: Kos Pharmaceuticals Drug-Delivery Company Intelligence Report to their offering.

Industry and commercial interest in drug delivery has been building steadily. The benefits to patients can be seen in improved compliance and medical outcomes, while the pharmaceutical industry is able to extend patent protection through novel delivery regimes and bring new therapies to the market that would, previously, have been impossible. These detailed company reports bring into focus the companies which driving growth and innovation in drug delivery. Over 140 leading players are examined with details for Company Overview, Key Personnel, Key Milestones, Products/Technologies, Research Strategy, Agreements, Financial Data and Associated Companies (if any) provided for each.

Topics Covered

1. Key Personnel

2. Company Overview

3. Key Milestones

4. Products/Technologies

5. Research Activities

6. Agreements

7. Key Financial Data

8. Associated Companies

9. Competition

Summary

Kos Pharmaceuticals Inc is a fully-integrated specialty pharmaceutical company engaged in developing, commercialising, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases. The company's principal product development strategy is to reformulate existing pharmaceutical products to improve safety, efficacy, or patient compliance. The company currently markets Niaspan and Advicor for the treatment of cholesterol disorders and Azmacort for the treatment of asthma. Kos is developing additional products and has proprietary drug-delivery technologies in solid-dose and aerosol metered-dose inhalation administration.

For more information visit http://www.researchandmarkets.com/reports/c32127

Source: Business Wire

More News in this Category